The “7th International Mutant p53 Workshop” will bring together world leading clinicians and researchers in the p53 field to discuss major advancements and challenges. This forum will advance understanding of this vital tumour protein through discussion of unpublished results, sharing of ideas and reagents, strengthening existing networks and opening opportunities to establish new collaborations. The workshop will also provide a great opportunity to foster young students and postdocs in this field.
The crucial protective role of the tumor suppressor p53 against cancer has propelled it to the heart of cancer biology for over 3 decades. Recent developments in the p53 field have expanded awareness of its contribution beyond vital stress responses, to fundamental key physiological functions such as DNA repair and metabolic regulation. Of particular interest is the advancement in our understanding of mutant p53. Mutations in p53 are the most common genetic events in human cancer, spanning every single cancer type and reaching an almost 100% incidence in certain cancers. These include the following: high-grade serious ovarian cancer, triple negative breast cancer, esophageal cancer, and colorectal cancer. Li Fraumeni, an important rare genetic disease, is attributed to inherited p53 mutations that result in early cancer onset. The fundamental involvement of p53 in cancer biology defines it as a key protein for ongoing basic and translational cancer research. This field is unique in the sense that it crosses all tumour streams. This meeting will be of interest to researchers in cancer biology, clinicians, and to members from industry, and provide a unique opportunity to extend basic research on p53 to clinical translational developments.
The workshop will take place in the new Victorian Comprehensive Cancer Centre in Melbourne, coinciding with its inauguration in 2016. Invited to the workshop will be international experts in the p53 field, many of whom are the world leaders in basic and translational cancer research, including: Sir Prof. David Lane and Prof Arnold Levine (the two discoverers of the tumour suppressor protein p53), Sir Alan Fersht, and Profs Karen Vousden, Moshe Oren, Carol Prives, Guillermina Lozano, David Malkin, Varda Rotter, Klas Wiman, Ute Moll, Michael Resnick, Gerard Zambetti, Giovanni Blandino, Pierre Hainaut, Gerry Melino, Kanaga Sabapathy, Galina Salivanova, Wei Gu, Hau Lu, Andreas Strasser and other outstanding p53 experts.
Major topics covered at this three-day Workshop will include:
- Mutant p53 animal models (mice, zebra fish, flies)
- Mutant p53 and Li-Fraumeni syndrome
- Mutant p53 regulation
- Mutant p53 gain-of-functions
- Mutant p53 structure
- Mutant p53 therapeutics
Organizers: Sir Prof. David Lane, Prof. Arnold Levine, Prof. Ygal Haupt
Please note that registrations will openly shortly.